Posaconazole delayed-release tablets in paediatric haematology-oncology patients.
Administration, Oral
Adolescent
Antifungal Agents
/ pharmacokinetics
Child
Child, Preschool
Delayed-Action Preparations
/ pharmacokinetics
Female
Hematologic Neoplasms
/ microbiology
Humans
Male
Mycoses
/ drug therapy
Retrospective Studies
Tablets
/ administration & dosage
Triazoles
/ pharmacokinetics
antifungal agents
antifungal target
deep fungal infection
paediatric malignancy
posaconazole
posaconazole delayed-release tablet (DRT)
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
27
01
2020
revised:
26
03
2020
accepted:
27
03
2020
pubmed:
5
4
2020
medline:
30
1
2021
entrez:
5
4
2020
Statut:
ppublish
Résumé
To date, there are few studies that describe pharmacokinetics, safety and efficacy of posaconazole delayed-release tablet (DRT) formulation in the paediatric population. We evaluated retrospectively posaconazole plasma concentrations and safety of posaconazole DRT in paediatric haematology-oncology patients. Posaconazole DRT was assessed in 28 haematological paediatric patients with a median age 15 of years (range 5-18) and a median body weight of 50 kg (range 22-83 kg). Twenty-one patients received posaconazole DRT as prophylaxis and 7 patients as therapy. As prophylaxis, the median daily dose was 5.5 mg/kg/day (range 2.2-22.2) with posaconazole trough level ≥ 0.7 μg/mL in 80% by first week, 62.5% by second week and 87.5% by fourth week. As therapy, the median daily dose was 4 mg/kg/day (range 3.3-4.5) with trough level ≥ 1 μg/mL 100% by first week, 80% by second week and 33.4% by fourth week. Posaconazole DRT is feasible in paediatric patients capable to swallow tablets. Specific pharmacokinetic studies are needed.
Sections du résumé
BACKGROUND
BACKGROUND
To date, there are few studies that describe pharmacokinetics, safety and efficacy of posaconazole delayed-release tablet (DRT) formulation in the paediatric population.
OBJECTIVES
OBJECTIVE
We evaluated retrospectively posaconazole plasma concentrations and safety of posaconazole DRT in paediatric haematology-oncology patients.
PATIENTS AND METHODS
METHODS
Posaconazole DRT was assessed in 28 haematological paediatric patients with a median age 15 of years (range 5-18) and a median body weight of 50 kg (range 22-83 kg). Twenty-one patients received posaconazole DRT as prophylaxis and 7 patients as therapy.
RESULTS
RESULTS
As prophylaxis, the median daily dose was 5.5 mg/kg/day (range 2.2-22.2) with posaconazole trough level ≥ 0.7 μg/mL in 80% by first week, 62.5% by second week and 87.5% by fourth week. As therapy, the median daily dose was 4 mg/kg/day (range 3.3-4.5) with trough level ≥ 1 μg/mL 100% by first week, 80% by second week and 33.4% by fourth week.
CONCLUSIONS
CONCLUSIONS
Posaconazole DRT is feasible in paediatric patients capable to swallow tablets. Specific pharmacokinetic studies are needed.
Substances chimiques
Antifungal Agents
0
Delayed-Action Preparations
0
Tablets
0
Triazoles
0
posaconazole
6TK1G07BHZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
604-609Informations de copyright
© 2020 Blackwell Verlag GmbH.
Références
Dvorak CC, Steinbach WJ, Brown JM, Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2005;36:621-629.
Castagnola E, Cesaro S, Giacchino M, et al. Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J. 2006;25:634-639.
Arrieta AC, Sung L, Bradley JS, et al. A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia. PLoS ONE. 2019;26(14):e0212837.
Maertens JA, Girmenia C, Brüggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73:3221-3230.
Döring M, Cabanillas Stanchi KM, Queudeville M, et al. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2017;143:1281-1292.
Vicenzi EB, Cesaro S. Posaconazole in immunocompromised pediatric patients. Expert Rev Anti Infect Ther. 2018;16:543-553.
Jancel T, Shaw PA, Hallahan CW, et al. Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review. J Clin Pharm Ther. 2017;42:75-79.
Campoli P, Al Abdallah Q, Robitaille R, et al. Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob Agents Chemother. 2011;55:5732-5739.
Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15(8):e327-e340.
Vicenzi EB, Calore E, Decembrino N, et al. Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients. Eur J Haematol. 2018;100:315-322.
Soysal A. Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole. Infection and Drug Resistance. 2015;8:321-331.
Tragiannidis A, Herbrüggen H, Ahlmann M, et al. Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents. J Antimicrob Chemother. 2019;74:3573-3578.
Wass EN, Hernandez EA, Sierra CM. Comparison of the efficacy of posaconazole delayed release tablets and suspension in pediatric hematology/oncology patients. J Pediatr Pharmacol Ther. 2020;25:47-52.